Paclitaxel oral - Solural PharmaAlternative Names: SOL606
Latest Information Update: 10 Dec 2015
At a glance
- Originator Solural Pharma
- Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Dec 2015 Preclinical trials in Cancer in Denmark (PO) prior to December 2015 (Solural pipeline, December 2015)